Mitochon Pharmaceuticals
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
970 Cross Ln, Blue Bell, Pennsylvania, 1...Phone Number
(215) 313-3905Website
www.mitochonpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Mitochon Pharmaceuticals
Mitochon Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that target mitochondrial dysfunction to treat serious neurodegenerative and neuromuscular diseases, including ALS, Huntington's Disease, and Parkinson's Disease. The company aims to address significant unmet medical needs by correcting mitochondrial dysfunction, which is linked to various diseases. Led by a team with over 100 years of combined experience, Mitochon is pioneering a unique platform of chemical uncouplers to modify disease progression. Their innovative approach seeks to enhance cellular function and promote survival through increased energy expenditure.Explore more
Mitochon Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mitochon Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Mitochon Pharmaceuticals
Website visits: Recent activity has been detected on your website
Mitochon Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Mitochon Pharmaceuticals has new funding data
Earning: See what the market has to say on Mitochon Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Mitochon Pharmaceuticals launches new products
Check if Mitochon Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Mitochon Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Mitochon Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at Mitochon Pharmaceuticals
Find more new buyers
Compare Similar Companies to Mitochon Pharmaceuticals
Compare insights from companies similar to Mitochon Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mitochon Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Mitochon Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Mitochon Pharmaceuticals.
Mitochon Pharmaceuticals financials insights
Gather financial insights about Mitochon Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Multiple Rounds
$3.3M
2013
Debt
$450K
2014
Unspecified
$500K
2015
Debt
$4.6M
Series A
$1.1M
2016
Private Equity
$799K
Mitochon Pharmaceuticals Tech Stack
A closer look at the technologies used by Mitochon Pharmaceuticals
See more technologies
Mitochon Pharmaceuticals News & Media
Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
Berwyn, Pennsylvania--(Newsfile Corp. - February 4, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) granted the Company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury."This new patent, covering acute indications, joins our two patents covering our primAnnovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
Berwyn, Pennsylvania--(Newsfile Corp. - February 2, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin-α (PFT-α) after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent.The pAnnovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 11-14, 2021.The on-demand presentation will be available beginning January 11 at 6:00 a.m. EST and can be accessed through the regisAnnovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Mitochon Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Mitochon Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that target mitochondrial dysfunction to treat serious neurodegenerative and neuromuscular diseases, including ALS, Huntington's Disease, and Parkinson's Disease. The company aims to address significant unmet medical needs by correcting mitochondrial dysfunctio... Read More
